+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 21Years +
All Genders
ID05329129

Observational Registry of OssDsign Bone Graft Substitutes in Spine Fusion Surgery Collecting Real-World Clinical Outcomes and Safety Data

Led by OssDsign · Updated on 2026-10-28

450

Participants Needed

16

Research Sites

1 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to collect information on the clinical outcomes and real-world use of OssDsign bone graft substitutes in patients who require spine fusion surgery. The study is a multi-center, prospective, observational registry involving up to 25 sites in the US. It focuses on patients diagnosed with degenerative disc disease or spinal stenosis who undergo spine fusion with OssDsign bone grafts. Participants receive commercially available OssDsign Catalyst bone graft substitutes, which are osteoconductive, resorbable, porous, and made of 100% nano synthetic calcium phosphate. The study will follow patients for up to 24 months 90 days after their index spine fusion surgery where the bone graft was implanted. The primary outcome measured is the rate of bone fusion approximately 12 months after surgery. During the study, participants will undergo clinical and radiographic follow-up evaluations including quality of life questionnaires such as the Oswestry Disability Index, Neck Disability Index, Visual Analog Scale, and Short Form 36 at multiple time points up to 24 months. Neurological function and presence of bone fusion will also be assessed at 6, 12, and 24 months. Safety reviews of device-related adverse events will be conducted throughout the study period.

CONDITIONS

Brief Title

OssDsign® Spine Registry Study ("Propel")

Research Team

J

jeff Feldhaus

A

Anne McKibbin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here